The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
ACQ2 by Acquired
00:00
Dual Mechanisms for Treating Diabetes and Obesity
The speaker was inspired by a colleague's work in a pharma setting to develop a drug that can target both type two diabetes and obesity simultaneously. The drug, Jilpewon, is designed to increase insulin levels and lower another hormone called glucogram to treat diabetes. It also includes a safety switch to prevent hypoglycemia. Additionally, Jilpewon targets weight loss by acting on the brain, the main organ for regulating eating habits, with some effects on the peripheral nervous system.
Transcript
Play full episode
